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Sir
We read with interest the article by Koukourakis et al (2000a)
describing the use of radiolabelled Caelyx to study the accumula-
tion of the polyethylene glycol (PEG)-liposomes in glioblastomas
and metastatic brain tumours, and would like to take the opportu-
nity to make some principal remarks regarding the applied
radiolabelling procedure.
To facilitate imaging of the accumulation of the liposomes in
the tumours, the authors labelled the liposomal formulation with
technetium-99m-diethylenetriamine pentaacetic acid (
99mTc-
DTPA). This labelling method was described previously in more
detail by the same group (Koukourakis et al, 1999). However, we
have some major concerns about the labelling method and
imaging protocol used in their studies (Koukourakis et al,
1999, 2000a,b).
The applied labelling method is based on the assumption that
adding
99mTc-DTPA to the PEG-liposomes (in the Caelyx formula-
tion) results in radiolabelled liposomes. This method, which has
not been described in the literature before, is expected to yield an
unstable radiolabelled product, since there is no driving force that
will facilitate the hydrophilic
99mTc-DTPA to pass the lipid bilayer
and entrap the radiolabel inside the liposome. Moreover, the
described quality control method (Koukourakis et al, 1999,
2000a,b) does not discriminate between free
99mTc-DTPA and lipo-
some-associated
99mTc-activity. The chromatographic method
applied can distinguish between reduced
99mTcO2 and unreduced
99mTcO4
-, however, it is more essential to discriminate between lipo-
some-associated
99mTc-activity and
99mTc-DTPA in the preparation.
The proper way to examine this, would be to elute a sample of the
radiolabelled liposomes on a gelpermeation column as described
previously (Dams et al, 2000; Harrington et al, 2001). The (radiola-
belled) liposomes will elute with the void volume in the early
fractions, whereas the non-liposome-associated radiolabel (both as
99mTc-DTPA,
99mTcO2, and
99mTcO4
-) will elute in later fractions.
Our attempts to reproduce the labelling method as described by
Koukourakis et al (2000a) failed. Analysis of the labelling mixture
by instant thin layer chromatography (ITLC) according to
Koukourakis et al (2000a) showed the same results as described
in their article, suggesting a labelling efﬁciency of approximately
80%. However, analysis on a Sephadex G25-column revealed that
only 1% of the
99mTc activity was associated with the liposomes
and the majority of the activity eluted in later fractions (Figure
1). This was conﬁrmed by ITLC on silica strips in sodium citrate,
a method to distinguish
99mTc-DTPA and
99mTc-liposomes
described previously (Cao and Suresh, 2000).
Our second point of concern is the chosen time-point of
imaging. The patients were imaged at 2 h after infusion of the lipo-
somes (Koukourakis et al, 2000a). Harrington et al (2001) showed
that clear visualization of solid tumours with
111In-labelled long-
circulating PEG-liposomes was achieved not earlier than 48–72 h
after injection, due to the high blood background signal at earlier
time-points. These ﬁndings are in line with our clinical study in
patients with infectious or inﬂammatory disease, imaged with
similar
99mTc-PEG-liposomes, labelled with
99mTc-hexamethylpro-
pylene-amine-oxime (Dams et al, 2000). Therefore, it appears
that the images showing liposome uptake in the tumours
(Koukourakis et al, 2000a) represent the accumulation of
99mTc-
DTPA, rather than uptake of the radiolabelled Caelyx.
99mTc-DTPA
was used in the past for diagnosis of a disrupted blood–brain
barrier in brain tumours, before the CT and MRI era (Hauser et
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Figure 1 Elution proﬁle of
99mTc-DTPA-Caelyx
1 (labelled according to
Koukourakis et al, 1999) and
111In-oxinate-Caelyx
1 (labelled according to
Laverman et al, 2001) on a 10 ml Sephadex G25 column. A sample of
100 ml was applied. Twenty consecutive fractions of 1 ml were eluted with
5% glucose and the activity of each fraction was counted in a gamma-coun-
ter. Note that the radiolabelled liposomes elute in fractions 3–5, whereas
the free radiolabel elutes in fractions 6–14. *Correspondence: P Laverman; E-mail: p.laverman@nugen.azn.nl
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99mTc-DTPA is a well-known agent for
evaluation of renal function. It is cleared rapidly and efﬁciently
from the circulation by glomerular ﬁltration. This might explain,
for liposomes, the unusual, rapid accumulation of activity in the
tumours. In our opinion, the authors should have performed,
and shown – at least in some patients – a control
99mTc-DTPA
scan, to rule out that the liposome scan represents free
99mTc-
DTPA instead of radiolabelled Caelyx.
A better approach to label Caelyx would be the labelling with
indium-111-oxine (
111In-oxine). This easy method will yieldradio-
labelled liposomes with good radiochemical yield (480%) and
good in vivo stability (Laverman et al, 2001). An additional advan-
tage is the longer physical half-life of
111In, which enables the
acquisition of delayed images and thus better visualization of the
tumours (Harrington et al, 2001).
In summary, scintigraphic techniques are very helpful in inves-
tigating the in vivo distribution of (new) pharmaceuticals, but
should only be performed using well-established labelling techni-
ques and quality control methods. The results presented by
Koukourakis et al (1999, 2000a,b) should therefore be interpreted
with caution.
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Sir
In these previous studies we provided a simple method to label
Caelyx by incubation of 5 mg of the ready-to-use solution with
20 mCi of
99mTc-DTPA. Instant thin layer chromatography (ITLC)
suggested an 80% labelling (Koukourakis et al, 1999), which is also
a result found by Dr Laverman and colleagues. As additional more
sophisticated analysis, performed by the later research group, failed
to conﬁrm this ﬁnding, it was suggested that the tumour and body
imaging obtained in our studies is rather a result of
99mTc-DTPA
and not of labelled liposomes.
99mTc-DTPA is currently used in the evaluation of renal func-
tion, and as well noted by Dr Laverman, this is rapidly cleared
from the kidneys. Two hours following injection, the imaging qual-
ity of kidneys is really poor.
99mTc-DTPA can give good images of
gliomas, probably as a result of the high tumour vascularization or
even of the disrupted blood–brain barrier, which allows a net
contrast between normal and abnormal brain. However, imaging
of other tumours with
99mTc-DTPA is questionable.
*Correspondence: MI Kourakis; E-mail: targ@her.forthnet.gr
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